Our research focus
The LIMCR (Laboratory for Immunological and Molecular Cancer Research), which is integrated in the Third Medical Department of the Paracelsus Medical University Hospital Salzburg, was established by Prof. Richard Greil in 2005. The main focus of the laboratory is the research on leukemia with a specialization on chronic lymphatic leukemia (CLL), myelodysplastic syndromes (MDS) and acut myeloid leukemia (AML).
The mission of our laboratory and the Third Medical Department is to implement systematically, and as quickly as possible, knowledge gained from translational and basic scientific research in medical practice and thereby offering patient-oriented and tailored therapy. As a consequence, the LIMCR maintains a close connection with the Clinical Trial Center and the Everyday Clinical Practice to ensure maximum synergy and efficacy in cancer research.
Through translational und international competitive research our team of medical scientists and biologists contributes to a better understanding of current therapeutic concepts and the development of novel treatment strategies.
In 2014 we founded together with the Paris Lodron University Salzburg (PLUS) the “Cancer Cluster Salzburg“(CCS), a network to strengthen collaboration and synergism in cancer research in Salzburg. For more details visit our CCS Homepage: www.cancercluster-salzburg.at
Furthermore our annual International CLL Workshop provides an update of the most recent insights into basic and clinical aspects of this disease. More information can be found on our CLL Workshop homepage
Group leader: Dr. Nadja Zaborsky
``In principle, the cells of the immune system (NK cells, T cells) are able to combat cancer. However, cancer cells developed mechanisms for immune escape, which enables unhindered tumor growth. Immune therapies aim at reinvigorating the body’s own immune system to improve cancer treatment. In our working group, we are analyzing the interplay between genetic changes in cancer cells and alterations in immune cell composition and functionality, which is important to improve current immune therapy approaches.``